INFECTIONS IN OCRELIZUMAB RECIPIENTS FROM PHASE III STUDIES

被引：0
|
作者：
Gavin, Giovannoni [1 ]
Hans-Peter, Hartung [2 ]
Giancarlo, Comi [3 ]
Jerome, de Seze [4 ]
Bernhard, Hemmer [5 ]
Ludwig, Kappos [6 ]
Xavier, Montalban [7 ]
Krzysztof, Selmaj [8 ]
Nicole, Mairon [9 ]
Jerry, Wolinsky [10 ]
机构：
[1] Queen Mary Univ London, London, England
[2] Heinrich Heine Univ Dusseldorf, Fac Med, Dusseldorf, Germany
[3] Univ Vita Salute San Raffaele, Milan, Italy
[4] Univ Hosp Strasbourg, Strasbourg, France
[5] Tech Univ Munich, Munich, Germany
[6] Univ Hosp Basel, Basel, Switzerland
[7] Univ Toronto, Toronto, ON, Canada
[8] Med Univ Lodz, Lodz, Poland
[9] F Hoffmann La Roche Ltd, Basel, Switzerland
[10] UTHealth, McGovern Med Sch, Houston, TX USA
来源：
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | 2018年 / 89卷 / 10期
关键词：
D O I：
10.1136/jnnp-2018-ABN.92
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
WED 187
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase III ocrelizumab trial halted by infections
    Nature Reviews Rheumatology, 2013, 9 (8) : 444 - 444
  • [2] Safety with Ocrelizumab in Rheumatoid Arthritis: Results from the Ocrelizumab Phase III Program
    Emery, Paul
    Rigby, William
    Tak, Paul P.
    Doerner, Thomas
    Olech, Ewa
    Martin, Carmen
    Millar, Laurie
    Travers, Helen
    Fisheleva, Elena
    PLOS ONE, 2014, 9 (02):
  • [3] Infusion-related reactions with ocrelizumab in phase III studies
    de Seze, J.
    Hauser, S. L.
    Kappos, L.
    Montalban, X.
    Pozzilli, C.
    Chognot, C.
    Julian, L.
    Koendgen, H.
    Zheng, H.
    Wolinsky, J. S.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 878 - 879
  • [4] SAFETY PROFILE OF BELATACEPT IN KIDNEY TRANSPLANT RECIPIENTS FROM A POOLED ANALYSIS OF PHASE II AND PHASE III STUDIES
    Grinyo, J.
    Charpentier, B.
    Medina Pestana, J.
    Vanrenterghem, Y.
    Vincenti, F.
    Shi, R.
    Agarwal, M.
    Thomas, D.
    Larsen, C.
    TRANSPLANT INTERNATIONAL, 2010, 23 : 59 - 60
  • [5] Safety Profile of Belatacept in Kidney Transplant Recipients from a Pooled Analysis of Phase II and Phase III Studies
    Grinyo, J.
    Charpentier, B.
    Pestana, J. Medina
    Vanrenterghem, Y.
    Vincenti, F.
    Shi, R.
    Agarwal, M.
    Thomas, D.
    Larsen, C. P.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 : 83 - 83
  • [6] The transition from phase II to phase III studies
    Tannock, I.
    Gulamhusein, A.
    Berthold, D. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] The Transition From Phase II To Phase III Studies
    Berthold, Dominik R.
    Gulamhusein, Aliya
    Jackson, John I.
    Tannock, Ian F.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (07) : 1150 - 1151
  • [8] The patient impact of 11 years of ocrelizumab treatment in multiple sclerosis: Long-term data from the Phase III OPERA and ORATORIO studies
    Hauser, Stephen
    Giovannoni, Gavin
    Filippi, Massimo
    Weber, Martin
    Montalban, Xavier
    Nicholas, Jacqueline
    Schneble, Hans-Martin
    Wang, Qing
    Kappos, Ludwig
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1052 - 1053
  • [9] NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies
    Traboulsee, Anthony
    Giovannoni, Gavin
    Bar-Or, Amit
    Comi, Giancarlo
    Hartung, Hans-Peter
    Havrdova, Eva
    Kappos, Ludwig
    Lublin, Fred
    Selmaj, Krzysztof
    Han, Jian
    Julian, Laura
    Belachew, Shibeshih
    Hauser, Stephen L.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (01) : 18 - 19
  • [10] The patient impact of 10 years of ocrelizumab treatment in multiple sclerosis: long-term data from the Phase III OPERA and ORATORIO studies
    Weber, Martin
    Kappos, Ludwig
    Hauser, Stephen
    Nicholas, Jacqueline
    Schneble, Hans-Martin
    Wang, Qing
    Giovannoni, Gavin
    Filippi, Massimo
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 350 - 351
12345